Abstract
Hepatitis C virus (HCV) affects millions of individuals worldwide. In most cases, HCV infection progresses to chronic liver disease and, subsequently, to liver cirrhosis and hepatocellular carcinoma. HCV is transmitted by the parenteral route, for example by transfusion of blood or blood products, injection during drug abuse, etc., and by the inapparent parenteral route (penetration of the virus through difficult-to-identify microlesions present on the skin or mucosae), for example, sexual exposure or household exposure to infected contacts, etc. The cost of chronic hepatitis C and its sequelae is high in both financial and human terms.
At present, only anti-HCV screening of blood/organ/tissue donors and universal precautions for the prevention of blood-borne infections are recommended for HCV prevention. Before the discovery of the main aetiological agent of non-A, non-B hepatitis (HCV), several randomised controlled clinical trials demonstrated that standard intramuscular immunoglobulin exerted a preventive effect on post-transfusional and sexual and /or horizontal transmission of non-A, non-B hepatitis. When serological tests for HCV infection became available, bimonthly inoculation of standard unscreened intramuscular immunoglobulin (prepared from plasma pools containing about 2% of anti-HCV—positive units) was demonstrated to significantly prevent sexually transmitted HCV infection. The immunoglobulin used contained high titres of anti-HCV neutralising antibodies (anti-E2 neutralisation of binding assay), whereas currently available commercial screened immunoglobulin (prepared from anti-HCV—negative blood units) did not. This finding suggested that anti-HCV neutralising antibodies are concentrated only in anti-HCV—positive units (which are currently discarded). Thus, anti-HCV hyperimmune globulin (HCIg) can be produced only from anti-HCV—positive units. The neutralising titre can be increased by the exclusive use of units with higher titres of neutralising antibodies. Unlike other hyperimmune globulins, which are produced from a limited number of selected donors, HCIg should be produced from a large number of units so as to contain neutralising antibodies to the different HCV strains. HCIg will have a number of advantages: (i) it is easy to produce and inexpensive; (ii) it has a long half-life, allowing infrequent administration; (iii) new additional viral inactivation procedures have been introduced to eradicate transmission of infection, and (iv) it may be possible to neutralise all the emerging HCV strains. HCIg could be used in all individuals at risk of HCV infection (sexual partners, haemodialysis patients, etc), in preventing reinfection of transplanted livers, and perhaps also in the treatment of chronic hepatitis C, alone or associated with other drugs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; 26Suppl. 1: 2S–10S
Davis GL. Treatment of acute and chronic hepatitis C. In: Davis GL, editor. Clinics in liver disease. Philadelphia (PA): W.B. Saunders Company, 1997: 615–30
Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26Suppl. 1: 62S–5S
Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26: 521–6
Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996; 125: 658–68
Hoofnagle HJ. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26Suppl. 1: 15S–20S
Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26Suppl. 1: 21–8S
Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26Suppl. 1: 34S–8S
Piazza M, Cacciatore L, Molinari V, et al. Hepatitis B not transmissible via fecal-oral route. Lancet 1975; II: 706–7
US Department of Health, Education, and Welfare. Hepatitis surveillance III. In: Hepatitis B transmission modes: evidence against enteric transmission, report 41. Atlanta (GA): Centers for Disease Control, 1977: 20–2
Alter MJ. The detection, transmission, and outcome of hepatitis C virus. Infect Agents Dis 1993; 2: 155–66
Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997; 26Suppl. 1: 66S–70S
Everhart JE, Di Bisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990; 112(7): 544–6
Peano GM, Fenoglio LM, Menardi G, et al. Heterosexual transmission of hepatitis C virus in family groups without risk factors. BMJ 1992; 305: 1473–4
Akahane Y, Aikawa T, Sugai Y, et al. Transmission of HCV between spouses. Lancet 1992; 339: 1059–60
Kao J-H, Chen P-J, Yang P-M, et al. Intrafamilial transmission of hepatitis C virus: the important role of infection between spouses. J Infect Dis 1992; 166: 900–3
Rice PS, Smith DB, Simmonds P, et al. Heterosexual transmission of hepatitis C virus. Lancet 1993; 342: 1052–3
Honda M, Kaneko S, Unoura M, et al. Risk of hepatitis C virus infections through household contact with chronic carriers: analysis of nucleotide sequences. Hepatology 1993; 17: 971–6
Osmond DH, Padian NS, Sheppard HW, et al. Risk factors for hepatitis C virus seropositivity in heterosexual couples. JAMA 1993; 269: 361–5
Bresters D, Mauser-Bunschoten EP, Reesink HW. Sexual transmission of hepatitis C virus. Lancet 1993; 342: 210–1
Hallam NF, Fletcher ML, Read SJ, et al. Low risk of sexual transmission of hepatitis C virus. J Med Virol 1993; 40: 251–3
Chang T-T, Liou T-C, Young K-C, et al. Intrafamilial transmission of hepatitis C virus: the important role of inapparent transmission. J Med Virol 1994; 42: 91–6
Idèo G, Bellati G, Pedraglio E, et al. Intrafamilial transmission of hepatitis C virus [letter]. Lancet 1990; 335(8685): 353
Akahane Y, Kojima M, Sugai Y et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994; 120: 748–52
Mauser-Bunschoten EP, Bresters D, Reesink HW. Transmission of hepatitis C virus to spouses. Ann Intern Med 1995; 122: 154–5
McGovern TW, Holtzmuller KC, Sherman KE, et al. Hepatitis C virus infections in U.S. families. In: Nishioka K, Suzuki H, Mishiro S, et al., editors. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994: 450–4
Ohmo T, Mizokama M, Lau JYN, et al. Sexual transmission of hepatitis C virus. In: Nishioka K, Suzuki H, Mishiro S, et al., editors. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994: 455–8
Setoguchi Y, Kajihara S, Hara T, et al. Analysis of nucleotide sequences of hepatitis C virus isolates from husband-wife pairs. J Gastroenterol Hepatol 1994; 9: 468–71
Chayama K, Kobayashi M, Tsubota A, et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol 1995; 22: 431–9
Kao J-H, Hwang Y-T, Chen P-J, et al. Transmission of hepatitis C virus between spouses: the important role of exposure duration. Am J Gastroenterol 1996; 91: 2087–90
Capelli C, Prati D, Bosoni P, et al. Sexual transmission of hepatitis C viras to a repeat blood donor. Transfusion 1997; 37 (4): 436–40
Salleras L, Bruguera M, Vidal J, et al. Importance of sexual transmission of hepatitis C in seropositive pregnant women: a case-control study. J Med Virol 1997; 52: 164–7
Alter HJ, Conry-Cantilena C, Meldpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26Suppl. 1: 29S–33S
Caporaso N, Ascione A, Stroffolini T, Investigators of an Italian Multicenter Group. Spread of hepatitis C virus infection within families. J Viral Hepatitis 1998; 5: 67–72
Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission of the hepatitis C viras and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997; 157: 1537–44
Koff RS. Prevention of hepatitis C virus infection. In: Davis GL, editor. Clinics in liver disease. Philadelphia (PA): W.B. Saunders Company, 1997: 603–13
U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47(RR-19): 1–39
Knodell RG, Conrad ME, Ginsberg AL, et al. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1976; I: 557–61
Kuhns WJ, Prince AM, Brotman B, et al. A clinical and laboratory evaluation of immune serum globulin from donors with a history of hepatitis: attempted prevention of post-transfusion hepatitis. Am J Med Sci 1976; 272: 255–61
Seeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. Gastroenterology 1977; 72: 111–21
Knodell RG, Conrad ME, Ishak KG. Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis. Role of γ-globulin prophylaxis in its prevention. Gastroenterology 1977; 72: 902–9
Sanchez-Quijano A, Pineda JA, Lissen E, et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1988; I: 1245–9
al-Khaja N, Roberts DG, Belboul A, et al. Gamma globulin prophylaxis to reduce post-transfusion non-A, non-B hepatitis after cardiac surgery with cardiopulmonary bypass. Scand J Thor Cardiovasc Surg 1991; 25: 7–12
Seeff LB, Hoofnagle JH. Immunoprophylaxis of viral hepatitis. Gastroenterology 1979; 77: 161–82
Sugg U, Schneider W, Hoffmeister HE, et al. Hepatitis B immune globulin to prevent non-A, non-B post-transfusion hepatitis. Lancet 1985; I: 405–6
Simm N. Prevention of non-A, non-B hepatitis in haemodialysis patients by hepatitis B immunoglobulin. Lancet 1984; II: 1047
Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 1987; 156: 56–63
van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994; 344: 1475–9
Jarvis LM, Watson HG, McOmish F, et al. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused haemophiliacs. J Infect Dis 1994; 170: 1018–22
Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children. Lancet 1994; 343: 388–90
Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135–40
Choo Q-L, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294–8
Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C viras infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792–96
Farci P, Shimoda A, Wong D, et al. Prevention of HCV infection in chimpanzees by hyperimmune serum against the hypervariable region (HVR1): emergence of neutralization escape mutants in vivo [abstract]. Hepatology 1995; 22 (Pt 2): 220
Piazza M, Chien D, Quan S, Houghton M. Lack of antibodies to the envelope glycoproteins of hepatitis C virus in immunoglobulin preparations from screened donors. J Biol Res — Boll Soc It Biol Sper 1996; 72: 69–70
Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C viras to CD81. Science 1998; 282: 938–41
Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of Immune globulin on the prevention of experimental hepatitis C viras infection. J Infect Dis 1996; 173: 822–8
Yu MW, Guo ZP, Mason BL, et al. Presence of protective antibodies in an experimental intravenous immune globulin prepared from anti-HCV positive donor units [abstract no. H13]. 5th International Meeting on Hepatitis C Virus and Related Viruses: 1998 Jun 25–28; Venice, 223
Krawczynski K, Fattom A, Sapan C, et al. Experimental treatment of HCV infection: passive anti-HCV transfer in acutely infected chimpanzees [abstract SS5/28]. 34th Annual Meeting of European Association for the Study of Liver: 1999 Apr 8–12; Naples, 59
Feray C, Gigou M, Samuel D, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998; 128: 810–6
Ishii K, Rosa D, Watanabe Y, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998; 28: 1117–20
Pessoa MG, Wright TL. Hepatitis C infection in transplantation. In: Davis GL, editor. Clinics in liver disease. Philadelphia (PA): W.B. Saunders Company, 1997: 663–90
Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22: 1863–73
Koff RS. Therapy of hepatitis C: cost-effectiveness analysis. Hepatology 1997; 26Suppl. 1: 152S–5S
Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65
Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866–74
Piazza M. Immunoglobulin transmits hepatitis C. True or false? Hepatology 1999; 29: 299–300
Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee (ACIP). Recommendations for protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 1985; 34(22): 313–35
Centers for Disease Control. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45(RR-15): 1–30
World Health Organization memoranda. Public health control of hepatitis A: memorandum from a WHO meeting. WHO Bull 1995; 73(1): 15–20
Piazza M, Sagliocca L, Tosone G, et al. More evidence on safety of intramuscular immune serum globulin produced from plasma unscreened for anti-hepatitis C virus antibodies. Arch Intern Med 1998; 158: 807–8
Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994; 331: 1649–50
Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996; 104Suppl. 1: 35–42
Piazza M in Koretz RL. Less than an ounce of prevention [see comment]. Gastroenterology 1998; 115: 234–6
Fattom A, Krawczynski K. Immunotherapy as a treatment for hepatitis C infection [abstract]. Evaluation in chimpanzees experimentally infected with HCV [abstract 8]. IBC’s 5th Annual Conference on Hepatitis: 1999 Jan 25–26; St. Pete Reach (FL)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Piazza, M., Sagliocca, L., Tosone, G. et al. Prophylaxis of Hepatitis C with Intramuscular Immunoglobulin. BioDrugs 12, 291–300 (1999). https://doi.org/10.2165/00063030-199912040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199912040-00006